Top

Published in:

01-01-2013 | Epidemiology

Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer

Authors: Windy Dean-Colomb, Kenneth R. Hess, Elliana Young, Terrie G. Gornet, Beverly C. Handy, Stacy L. Moulder, Nuhad Ibrahim, Lajos Pusztai, Daniel Booser, Vicente Valero, Gabriel N. Hortobagyi, Francisco J. Esteva

Published in: Breast Cancer Research and Treatment | Issue 2/2013

Abstract

Bone is the most common site of metastasis of breast cancer, affecting most women with advanced disease. Procollagen type I N-terminal propeptide (P1NP), osteocalcin, CTX, and IL-6 are markers of bone turnover. Our objective was to determine whether serum levels of these proteins have clinical utility as predictors of breast cancer metastasis to bone. Blood was collected before treatment from 164 patients with stage I–III breast cancer from September 2001 to December 2008. Serum levels of P1NP, CTX, IL-6, and OC were measured using an automated immunoassay system. Correlations of the levels of these markers with time to bone metastasis development and with overall survival (OS) rate were assessed using Cox proportional hazards regression analysis and the Kaplan–Meier method. Fifty-five patients with stage I–III disease at the time of blood sample collection subsequently experienced metastasis to bone. A baseline P1NP level of at least 75 ng/mL predicted increased risk of bone metastasis (hazard ratio, 2.7 [95 % confidence interval, 1.2–6.0]; P = 0.031) and a poor OS rate (P = 0.031). Serum P1NP levels at or above 75 ng/mL correlate with a short time to development of bone metastasis and low overall survival in patients with stage I–III breast cancer.

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef

Scheid V, Buzdar AU, Smith TL, Hortobagyi GN (1986) Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. Cancer 58:2589–2593PubMedCrossRef

Alexandraki I (2011) The United States-Mexico border: an area in need of cancer screening interventions. J Women’s Health 20:653–655CrossRef

Mehta RS, Barlow WE, Albain KS et al (2012) Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 367:435–444PubMedCrossRef

Lipton A (2003) Bone metastases in breast cancer. Curr Treat Options Oncol 4:151–158PubMedCrossRef

Lipton A, Costa L, Ali S, Demers L (2001) Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 28:54–59PubMedCrossRef

Bellahcene A, Kroll M, Liebens F, Castronovo V (1996) Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res 11:665–670PubMedCrossRef

Buijs JT, Henriquez NV, van Overveld PG et al (2007) Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 67:8742–8751PubMedCrossRef

Chao TY, Yu JC, Ku CH et al (2005) Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients. Clin Cancer Res 11:544–550PubMed

10.

Diel IJ, Solomayer EF, Seibel MJ et al (1999) Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. Clin Cancer Res 5:3914–3919PubMed

11.

Wada N, Ishii S, Ikeda T, Enomoto K, Kitajima M (1999) Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer. Anticancer Res 19:4515–4521PubMed

12.

Wu YY, Janckila AJ, Ku CH et al (2010) Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis. BMC Cancer 10:158PubMedCrossRef

13.

Lipton A, Costa L, Ali SM, Demers LM (2001) Bone markers in the management of metastatic bone disease. Cancer Treat Rev 27:181–185PubMedCrossRef

14.

Samoszuk M, Leuther M, Hoyle N (2008) Role of serum P1NP measurement for monitoring treatment response in osteoporosis. Biomark Med 2:495–508PubMedCrossRef

15.

Lipton A (2008) Emerging role of bisphosphonates in the clinic–antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 34(Suppl 1):S25–S30PubMedCrossRef

16.

Nangia JR, Ma JD, Nguyen CM, Mendes MA, Trivedi MV (2012) Denosumab for treatment of breast cancer bone metastases and beyond. Expert Opin Biol Ther 12:491–501PubMedCrossRef

17.

Barton MK (2011) Denosumab an option for patients with bone metastasis from breast cancer. CA Cancer J Clin 61:135–136PubMedCrossRef

18.

Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 29:1125–1132PubMedCrossRef

19.

Lipton A, Steger GG, Figueroa J et al (2007) Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 25:4431–4437PubMedCrossRef

20.

Andersen PK, Gill RD (1982) Cox’s regression model for counting processes: a large sample study. Ann Stat 10:1100–1120CrossRef

21.

Tawara K, Oxford JT, Jorcyk CL (2011) Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Manag Res 3:177–189PubMed

22.

Koizumi M, Yonese J, Fukui I, Ogata E (2001) The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 87:348–351PubMedCrossRef

23.

Thurairaja R, Iles RK, Jefferson K, McFarlane JP, Persad RA (2006) Serum amino-terminal propeptide of type 1 procollagen (P1NP) in prostate cancer: a potential predictor of bone metastases and prognosticator for disease progression and survival. Urol Int 76:67–71PubMedCrossRef

24.

Oremek G, Sauer-Eppel H, Klepzig M (2007) Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas. Anticancer Res 27:1961–1962PubMed

25.

Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Luftner D (2007) The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer. Anticancer Res 27:1853–1862PubMed

26.

Marin L, Koivula MK, Jukkola-Vuorinen A, Leino A, Risteli J (2011) Comparison of total and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases. Ann Clin Biochem 48:447–451PubMedCrossRef

27.

Saarto T, Blomqvist C, Risteli J, Risteli L, Sarna S, Elomaa I (1998) Aminoterminal propeptide of type I procollagen (PINP) correlates to bone loss and predicts the efficacy of antiresorptive therapy in pre- and post-menopausal non-metastatic breast cancer patients. Br J Cancer 78:240–245PubMedCrossRef

28.

Tahtela R, Tholix E (1996) Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Anticancer Res 16:2289–2293PubMed

29.

Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529PubMedCrossRef

30.

McCloskey E, Paterson A, Kanis J, Tahtela R, Powles T (2010) Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer. Eur J Cancer 46:558–565PubMedCrossRef

31.

Esteva FJ, Guo H, Zhang S et al (2010) PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177:1647–1656PubMedCrossRef

32.

Ali SM, Esteva FJ, Hortobagyi G et al (2001) Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 19:3434–3437PubMed

33.

Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN (2001) Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 6:133–146PubMedCrossRef

34.

Esteva FJ (2004) Monoclonal antibodies, small molecules, and vaccines in the treatment of breast cancer. Oncologist 9:4–9PubMedCrossRef

35.

Aapro MS (2011) Denosumab for bone metastases from breast cancer: A new therapy option? J Clin Oncol 29: e419–e420; author reply e421–e414

36.

de Kluyver RL, Sayers TJ (2010) Breast cancer bone metastases: combination therapy targeting cancer cells and the tumor microenvironment. Cancer Biol Ther 9:551–553PubMedCrossRef

37.

Fizazi K, Lipton A, Mariette X et al (2009) Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27:1564–1571PubMedCrossRef

38.

Lee BL, Higgins MJ, Goss PE (2012) Denosumab and the current status of bone-modifying drugs in breast cancer. Acta Oncol 51:157–167PubMedCrossRef

39.

van der Pluijm G (2011) Breast cancer bone metastases: denosumab or zoledronic acid? Nat Rev Endocrinol 7:134–135PubMedCrossRef

40.

Paterson AH, Anderson SJ, Lembersky BC et al (2012) Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 13:734–742PubMedCrossRef

41.

Body JJ, Dumon JC, Gineyts E, Delmas PD (1997) Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer 75:408–412PubMedCrossRef

42.

Fornander T, Rutqvist LE, Wilking N, Carlstrom K, von Schoultz B (1993) Oestrogenic effects of adjuvant tamoxifen in postmenopausal breast cancer. Eur J Cancer 29A:497–500PubMedCrossRef

43.

Kong QQ, Sun TW, Dou QY et al (2007) Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer. Int J Biol Markers 22:214–220PubMed

44.

Leeming DJ, Delling G, Koizumi M et al (2006) Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion. Cancer Epidemiol Biomark Prev 15:1392–1395CrossRef

45.

Brasso K, Christensen IJ, Johansen JS et al (2006) Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate 66:503–513PubMedCrossRef

46.

Kim SW, Kim JS, Papadopoulos J et al (2011) Consistent interactions between tumor cell IL-6 and macrophage TNF-alpha enhance the growth of human prostate cancer cells in the bone of nude mouse. Int Immunopharmacol 11:862–872PubMedCrossRef

47.

Tang CH, Chuang JY, Fong YC, Maa MC, Way TD, Hung CH (2008) Bone-derived SDF-1 stimulates IL-6 release via CXCR4, ERK and NF-kappaB pathways and promotes osteoclastogenesis in human oral cancer cells. Carcinogenesis 29:1483–1492PubMedCrossRef

48.

Tsangari H, Findlay DM, Kuliwaba JS, Atkins GJ, Fazzalari NL (2004) Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. Bone 35:334–342PubMedCrossRef

49.

Blair JM, Zhou H, Seibel MJ, Dunstan CR (2006) Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 3:41–49PubMedCrossRef

50.

Wall KM, Nunez-Rocha GM, Salinas-Martinez AM, Sanchez-Pena SR (2008) Determinants of the use of breast cancer screening among women workers in urban Mexico. Prev Chronic Dis 5:A50PubMed

Title: Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer
Authors: Windy Dean-Colomb
Kenneth R. Hess
Elliana Young
Terrie G. Gornet
Beverly C. Handy
Stacy L. Moulder
Nuhad Ibrahim
Lajos Pusztai
Daniel Booser
Vicente Valero
Gabriel N. Hortobagyi
Francisco J. Esteva
Publication date: 01-01-2013
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-012-2374-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2013

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer

Trastuzumab administration during pregnancy: a systematic review and meta-analysis

Impact of breast cancer on anti-mullerian hormone levels in young women

Total energy intake and breast cancer risk in sisters: the Breast Cancer Family Registry

The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer

One-day core needle biopsy in a breast clinic: 4 years experience

Keynote webinar | Spotlight on antibody–drug conjugates in cancer